10 Feb Akron Biotech
Akron’s strategic focus is supplying and contract manufacturing GMP-compliant ancillary materials to enable the advancement of cell and gene therapies. Since 2006 Akron has supplied the cell and gene therapy market with the highest quality cytokines and growth factors, blood-derived products, media, transfection reagents, and other custom development services. Akron is an ISO 13485-certified company operating in line with cGMP guidelines and international standards. In April of 2022, Akron opened its second 110,000 sq. ft. GMP facility for the production of gene editing technologies and plasmid DNA. The facility is FDA 21 CFR Part 11 and Eudralex Vol 4 Annex 11 compliant to support the manufacture of high-quality ancillary materials and drug substances. Akron provides advanced therapy developers the scale, compliance, flexibility, and regulatory support to develop novel technologies from pre-clinical through to commercialization. www.akronbiotech.com
